Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.7K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K
Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Tumor Progression02:07

Tumor Progression

6.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.0K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic Remodeling of the Fibrotic Niche: Implications of Finerenone for Ovarian Insufficiency and Beyond.

Molecular reproduction and development·2026
Same author

Natural Compared With Artificial Cycle Endometrial Preparation for Frozen Embryo Transfer: A Systematic Review and Meta-analysis.

Obstetrics and gynecology·2026
Same author

Magnesium as a Bioenergetic Checkpoint Linking Mitochondrial Function, Metabolic Disease, and Aging.

Aging cell·2026
Same author

Obstructive Sleep Apnea and Risk for Thromboembolic Complication Among Patients With Polycystic Ovary Syndrome: A Retrospective Cohort Study.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer.

Cancer letters·2026
Same author

Targeted Vaginal Microbiome Modulation by Postbiotic Intervention Reduces Dysbiosis-Associated Pathogens in Infertile Women: A Pilot Study.

International journal of medical sciences·2026

Related Experiment Video

Updated: Nov 23, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K

UBE2C Drives Human Cervical Cancer Progression and Is Positively Modulated by mTOR.

An-Jen Chiang1,2, Chia-Jung Li2,3, Kuan-Hao Tsui2,3

  • 1Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan.

Biomolecules
|January 5, 2021
PubMed
Summary
This summary is machine-generated.

Ubiquitin conjugating enzyme E2 (UBE2C) is highly expressed in cervical squamous cell carcinoma (CESC), promoting cancer cell proliferation. UBE2C may serve as a potential molecular target for treating CESC.

Keywords:
UBE2Cbioinformationcervical cancerhuman papillomavirus

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.4K

Related Experiment Videos

Last Updated: Nov 23, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cervical cancer is a significant gynecological malignancy.
  • Targeted therapies offer advantages for cervical cancer treatment.
  • Ubiquitin conjugating enzyme E2 (UBE2C) is implicated in various tumor progressions, but its role in cervical squamous cell carcinoma (CESC) is unknown.

Purpose of the Study:

  • To investigate the role of UBE2C in the progression of cervical squamous cell carcinoma (CESC).
  • To determine if UBE2C expression correlates with clinical characteristics in CESC patients.
  • To explore UBE2C's potential as a therapeutic target for CESC.

Main Methods:

  • Tissue microarray analysis of 294 CESC patient samples.
  • In vitro experiments involving UBE2C overexpression and knockdown in cervical cancer cells.
  • In vivo studies to assess UBE2C's effect on tumor progression.
  • Analysis of the mTOR/PI3K/AKT signaling pathway.

Main Results:

  • UBE2C was found to be highly expressed in CESC tissues.
  • UBE2C expression correlated with clinical characteristics of CESC patients.
  • UBE2C overexpression enhanced, while knockdown reduced, cervical cancer cell proliferation in vitro.
  • UBE2C regulated the expression and activity of the mTOR/PI3K/AKT pathway in vivo.

Conclusions:

  • UBE2C is significantly involved in the progression of cervical squamous cell carcinoma (CESC).
  • UBE2C expression levels are associated with clinical features of CESC.
  • UBE2C influences cervical cancer cell proliferation via the mTOR/PI3K/AKT pathway.
  • UBE2C presents a potential molecular target for CESC treatment.